ClinicalTrials.gov
ClinicalTrials.gov Menu

Buprenorphine Detoxification With Two Types of Treatment. BBD III - 12

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00000230
Recruitment Status : Completed
First Posted : September 21, 1999
Last Update Posted : May 6, 2016
Sponsor:
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by:
University of Vermont

Brief Summary:
The purpose of this study is to evaluate buprenorphine and behavioral treatment with and without contingent payment on compliance with naltrexone.

Condition or disease Intervention/treatment Phase
Opioid-Related Disorders Drug: Buprenorphine Phase 2

Study Type : Interventional  (Clinical Trial)
Enrollment : 0 participants
Primary Purpose: Treatment
Official Title: Buprenorphine Detoxification With Two Types of Treatment. BBD III
Study Start Date : January 1995

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. Drug use
  2. Retention
  3. Weeks abstinent
  4. Weeks continuous abstinence
  5. Overall treatment outcome


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
Please contact site for information.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000230


Locations
United States, Vermont
Treatment Research Center
Burlington, Vermont, United States, 05401
Sponsors and Collaborators
University of Vermont
National Institute on Drug Abuse (NIDA)
Investigators
Principal Investigator: Warren Bickel, Ph.D. University of Vermont

ClinicalTrials.gov Identifier: NCT00000230     History of Changes
Other Study ID Numbers: NIDA-06969-12
R01DA006969 ( U.S. NIH Grant/Contract )
R01-06969-12
First Posted: September 21, 1999    Key Record Dates
Last Update Posted: May 6, 2016
Last Verified: August 1996

Additional relevant MeSH terms:
Opioid-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Buprenorphine
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Narcotic Antagonists